Huntington’s Disease Treatment Market is expected to grow from USD 365 million in 2022 to USD 1,517 million by 2030 : GreyViews
06 févr. 2023 16h00 HE
|
GreyViews
Pune India, Feb. 06, 2023 (GLOBE NEWSWIRE) -- The market has been studied for the below mentioned-segmentation and regional analysis for North America, Europe, Asia, South America, and the Middle...
Funding Renewed for Biotech Center, LSU One of Five Partners
06 déc. 2022 11h00 HE
|
LSU College of Engineering
BATON ROUGE, La., Dec. 06, 2022 (GLOBE NEWSWIRE) -- The Center for BioModular Multi-Scale Systems, or CBM2, was recently renewed for funding through the National Institutes of Health as a National...
RetinalGeniX Technologies, Inc. to Present at the Emerging Growth Conference Wednesday, October 26, 2022
24 oct. 2022 13h05 HE
|
RetinalGeniX Technologies, Inc.
PETALUMA, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- RetinalGeniX Technologies, Inc. OTCQB: RTGN to Present at the Emerging Growth Conference. RetinalGeniX Technologies, Inc. (RTGN) is pleased to...
Medical Device Packaging Market Size is projected to reach USD 61.27 Billion by 2030, growing at a CAGR of 8%: Straits Research
09 août 2022 09h20 HE
|
Straits Research
New York, United States, Aug. 09, 2022 (GLOBE NEWSWIRE) -- The primary function of healthcare packaging is to protect the products produced by the healthcare business. Healthcare items use packaging...
Vinay Mehindru, MD, MBA Appointed to RetinalGenix Technologies Inc. Board of Directors
26 juil. 2022 06h15 HE
|
RetinalGeniX Technologies, Inc.
PETALUMA, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- RetinalGenix™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGenix” or the “Company”), announced today the appointment of Vinay Mehindru, MD, MBA to the...
RetinalGeniX Technologies, Inc. Acquires DNA/GPS Inc.
06 juil. 2022 08h00 HE
|
RetinalGeniX Technologies, Inc.
PETALUMA, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), announced today the acquisition of DNA/GPS Inc.,...
AXIM Develops Quantitative Rapid Diagnostic Test for Lacritin; Now Boasts Four Dry Eye Disease Point-of-Care Biomarker Tests
27 avr. 2022 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting Dry Eye...
Sickle Cell Consortium Hosts 6th Annual Leadership Summit - Advocacy & Capacity-Building in the Digital Age
25 avr. 2022 08h00 HE
|
Sickle Cell Consortium
ATLANTA, April 25, 2022 (GLOBE NEWSWIRE) -- The Sickle Cell Consortium hosts the 6th Annual Leadership Summit and General Assembly of Patients, Caregivers, and Community-Based Organizations (CBOs)...
First AI-Powered ALS Educational Platform Launches for the Public
20 avr. 2022 11h30 HE
|
StoryFile
Los Angeles, CA, April 20, 2022 (GLOBE NEWSWIRE) -- StoryFile, an AI startup redefining the media landscape through its proprietary storytelling technology, announced the launch of its first...
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Cabaletta Bio, Inc. Investors with Losses to Secure Counsel Before Important April 29 Deadline in Securities Class Action – CABA
19 avr. 2022 17h15 HE
|
The Rosen Law Firm PA
NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cabaletta Bio, Inc. (NASDAQ: CABA): (i) pursuant and/or...